Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 12 of 12
Jan 9, 2026Despite promises of a gene therapy delivery platform avoiding viral vectors, Rampart Bioscience is closing, highlighting ongoing challenges in gene therapy innovation and delivery technologies.
TCB Team
Jan 9, 2026The startup’s lead candidate is Phase 2-ready and hits the same dual targets as Amgen’s therapy but may offer better dosing benefits. Their pipeline also positions them against Roche and Novo Nordisk programs in development.
TCB Team
Jan 9, 2026Alveus Therapeutics recently secured $160 million to advance a Phase 2-ready drug tackling obesity through dual GLP-1 and GIP receptor modulation. The startup's approach may offer dosing advantages and compete with established pharma players like Amgen, Roche, and Novo Nordisk.
TCB Team
Jan 8, 2026After two successful Phase 3 studies, GSK's bepirovirsen demonstrates functional cure rates for chronic hepatitis B patients, potentially providing an alternative to lifelong antiviral regimens.
TCB Team
Jan 7, 2026GSK’s bepirovirsen achieved its primary endpoint in late-stage clinical trials, potentially offering an alternative to lifelong antiviral treatments for patients with chronic hepatitis B infection. This development marks a significant step toward a functional cure for the disease.
TCB Team
Jan 7, 2026With rapid advancements and investments, China is closing the gap on biotech research and development. This change could reshape competitive dynamics and investment flows in the industry.
TCB Team
Jan 6, 2026The biotech company’s innovative RNAi-based therapies showed encouraging outcomes in early clinical trials targeting obesity, highlighting gene-silencing technology’s expanding role in metabolic diseases.
TCB Team
Jan 6, 2026Arrowhead Pharmaceuticals reported that its gene-silencing candidates were successful in helping people with obesity lose fat, marking an advancement in RNA medicine aimed at managing obesity.
TCB Team
Jan 6, 2026Arrowhead's gene-silencing drugs demonstrated efficacy in reducing fat accumulation in early obesity studies. This approach could complement existing therapies by tackling the biology of obesity through RNA interference technology.
TCB TeamMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.